Caprion–HistoGeneX and Viroclinics–DDL have announced a new strategic partnership to expand their global capabilities addressing the emerging needs for therapeutic and prophylactic solutions to target infectious diseases including COVID-19.
 
This partnership brings together the leadership of two prominent contract research organizations serving the pharmaceutical and biotechnology community with specialized assays and technologies relevant to clinical and preclinical studies aimed at developing vaccines and other therapies for infectious diseases.
 
By combining their respective expertise, the two companies offer a full suite of specialized services to support vaccine and antiviral studies along with a broad global presence, including sites in The Netherlands, Canada, USA, Belgium, UK, Australia and China.
 
“We are excited to partner with Caprion-HistoGeneX and combine the unique strengths of our companies to deliver first class contract research services to our customers developing innovative modalities to combat infectious diseases,” said Davide Molho DVM, the new CEO of Viroclinics-DDL.
 
The partnership allows for a seamless, integrated service experience for customers worldwide, with a broad service offering covering all stages of vaccine and antiviral development, ranging from preclinical and in-vitro research models to the deployment of custom-developed and off-the-shelf functional assays for monitoring vaccine efficacy. In addition to leveraging a broad selection of specialized platforms such as viral neutralization, flow cytometry, ELISpot and immuno-assays, the partnership will also provide access to an extended global network of clinical sample processing facilities across North America, South America, Europe, Africa and Asia, along with operational and logistical services including sample management and sampling kits.
 
“With our complementary competencies, we are able to fulfill the R&D and clinical outsourcing needs of the market. In the wake of the current COVID-19 pandemic, we believe that this joint initiative will bring vaccine and antiviral testing to the next level,” commented Martin LeBlanc, CEO of Caprion-HistoGeneX.